Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy

Walle, Thomas; Bajaj, Sunanjay; Kraske, Joscha A.; Rosner, Thomas; Cussigh, Christiane S.; Kälber, Katharina A.; Müller, Lisa; Strobel, Stefanie; Burghaus, Jana; Kallenberger, Stefan M.; Stein-Thöringer, Christoph; Jenzer, Maximilian; Schubert, Antje; Kahle, Steffen; Williams, Anja; Hoyler, Birgit; Zielske, Lin; Skatula, Renate; Sawall, Stefan; Leber, Mathias F.; Kunes, Russell; Krisam, Johannes; Fremd, Carlo; Schneeweiß, Andreas; Krauß, Jürgen; Apostolidis, Leonidas; Berger, Anne; Haag, Georg Martin; Zschäbitz, Stefanie; Halama, Niels; Springfeld, Christoph; Kirsten, Romy; Hassel, Jessica C.; Jäger, Dirk; Ungerechts, Guy

doi:10.1038/s43018-022-00420-y

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, vaccination is a pseudo-COVID-19 infection which trains the immune system [ 39 ]. Although vaccination has sometimes been associated cytokine release syndrome (CRS) in patients with cancer [ 40 ], correlations between mRNA vaccination and clinically relevant CRS diagnostic criteria remain unclear [ 41 ]. Benefit-risk ratios are still favorable for immunization.…”

Section: Discussionmentioning

confidence: 99%

Mucosal immunization with Lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 epitopes on the surface induces humoral and mucosal immune responses in mice

et al. 2023

View full text Add to dashboard Cite

Background The use of probiotic lactic acid bacteria as a mucosal vaccine vector is considered a promising alternative compared to the use of other microorganisms because of its “Generally Regarded as Safe” status, its potential adjuvant properties, and its tolerogenicity to the host. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease (COVID-19), is highly transmissible and pathogenic. This study aimed to determine the potential of Lactiplantibacillus plantarum expressing SARS-CoV-2 epitopes as a mucosal vaccine against SARS-CoV-2. Results In this study, the possible antigenic determinants of the spike (S1–1, S1–2, S1–3, and S1–4), membrane (ME1 and ME2), and envelope (E) proteins of SARS-CoV-2 were predicted, and recombinant L. plantarum strains surface-displaying these epitopes were constructed. Subsequently, the immune responses induced by these recombinant strains were compared in vitro and in vivo. Most surface-displayed epitopes induced pro-inflammatory cytokines [tumor necrosis factor alpha (TNF-α and interleukin (IL)-6] and anti-inflammatory cytokines (IL-10) in lipopolysaccharide-induced RAW 264.7, with the highest anti-inflammatory to pro-inflammatory cytokine ratio in the S1–1 and S1–2 groups, followed by that in the S1–3 group. When orally administered of recombinant L. plantarum expressing SARS-CoV-2 epitopes in mice, all epitopes most increased the expression of IL-4, along with induced levels of TNF-α, interferon-gamma, and IL-10, specifically in spike protein groups. Thus, the surface expression of epitopes from the spike S1 protein in L. plantarum showed potential immunoregulatory effects, suggesting its ability to potentially circumvent hyperinflammatory states relevant to monocyte/macrophage cell activation. At 35 days post immunization (dpi), serum IgG levels showed a marked increase in the S1–1, S1–2, and S1–3 groups. Fecal IgA levels increased significantly from 21 dpi in all the antigen groups, but the boosting effect after 35 dpi was explicitly observed in the S1–1, S1–2, and S1–3 groups. Thus, the oral administration of SARS-CoV-2 antigens into mice induced significant humoral and mucosal immune responses. Conclusion This study suggests that L. plantarum is a potential vector that can effectively deliver SARS-CoV-2 epitopes to intestinal mucosal sites and could serve as a novel approach for SARS-CoV-2 mucosal vaccine development.

show abstract

Section: Discussionmentioning

confidence: 99%

Mucosal immunization with Lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 epitopes on the surface induces humoral and mucosal immune responses in mice

et al. 2023

View full text Add to dashboard Cite

show abstract

Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors

Nelli

Giannarelli

Fabbri

et al. 2023

Cancer Immunol Immunother

View full text Add to dashboard Cite

BackgroundThe clinical implications of the third dose of coronavirus disease 2019 vaccines in patients receiving immune checkpoint inhibitors (ICIs) are currently unknown. We performed a prospective analysis of the Vax-On-Third study to investigate the effects of antibody response on immune-related adverse events (irAEs) and disease outcomes. MethodsRecipients of the booster dose of SARS-CoV-2 mRNA-BNT162b2 vaccine who had received at least one course of ICI treatment before vaccination for an advanced solid malignancy were eligible. ResultsThe current analysis included 56 patients with metastatic disease (median age: 66 years; 71% male), most of whom had a lung cancer diagnosis and were being treated with pembrolizumab-or nivolumabbased regimens. The optimal cut-point antibody titer of 3424 AU/mL allowed a dichotomization of recipients into low-responders (Low-R, < 3424 AU/mL) or high-responders (High-R, ≥ 3424 AU/mL). After a median follow-up time of 131 days, 20% of patients experienced moderate to severe irAEs without any recrudescence of immune toxicities preceding the booster dose. The frequencies of irAE before and after the third dose did not differ, but a signi cant increase in the cumulative incidence of immuno-related thyroiditis was observed within High-R subgroup. On multivariate analysis, an enhanced humoral response correlated with a better outcome in terms of durable clinical bene t, which resulted in a signi cant reduction in the risk of disease control loss but not mortality. ConclusionsOur ndings would strengthen the recommendation not to change immunotherapy plans based on current or future immunization schedules, implying that all these patients should be closely monitored.

show abstract

Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy

Cited by 2 publications

References 0 publications

Mucosal immunization with Lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 epitopes on the surface induces humoral and mucosal immune responses in mice

Mucosal immunization with Lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 epitopes on the surface induces humoral and mucosal immune responses in mice

Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors

Contact Info

Product

Resources

About